Qingdao NovelBeam Technology Co Ltd
SSE:688677
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.73
56.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Qingdao NovelBeam Technology Co Ltd
Cost of Revenue
Qingdao NovelBeam Technology Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Q
|
Qingdao NovelBeam Technology Co Ltd
SSE:688677
|
Cost of Revenue
-¥175.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Cost of Revenue
-¥486.1m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Cost of Revenue
-¥3.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-14%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Cost of Revenue
-¥13.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Cost of Revenue
-¥550.4m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Cost of Revenue
-¥5.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Qingdao NovelBeam Technology Co Ltd
Glance View
Qingdao NovelBeam Technology Co., Ltd. engages in the research and development of optics technology, the manufacture of optical instruments, and the provision of design solutions for medical, life science, laser, and micro-display projection applications. The company is headquartered in Qingdao, Shandong and currently employs 854 full-time employees. The company went IPO on 2021-02-26. Its main products of medical endoscope equipment include fluorescent endoscopes, fluorescent camera adapters/adaptive lenses, fluorescent light source modules and white light source modules. Its medical endoscopic equipment products are mainly used in abdominal endoscopic surgery such as liver and gallbladder and gastrointestinal surgery. Its optical products mainly include medical optical products, industrial and laser optical products, and biometric products. Among them, the biometric products include fingerprint devices, palmprint devices and related accessories. In addition, the Company also provides technical services and house leasing services. The firm distributes its products both in the domestic market and to overseas markets.
See Also
What is Qingdao NovelBeam Technology Co Ltd's Cost of Revenue?
Cost of Revenue
-175.3m
CNY
Based on the financial report for Dec 31, 2023, Qingdao NovelBeam Technology Co Ltd's Cost of Revenue amounts to -175.3m CNY.
What is Qingdao NovelBeam Technology Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-15%
Over the last year, the Cost of Revenue growth was -1%. The average annual Cost of Revenue growth rates for Qingdao NovelBeam Technology Co Ltd have been -20% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
